These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 23681955

  • 1. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial.
    Stamp LK, O'Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT.
    Arthritis Rheum; 2013 Jun; 65(6):1636-42. PubMed ID: 23681955
    [Abstract] [Full Text] [Related]

  • 2. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 3. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT.
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [Abstract] [Full Text] [Related]

  • 4. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Rheumatology (Oxford); 2012 Sep; 51(9):1670-6. PubMed ID: 22539486
    [Abstract] [Full Text] [Related]

  • 5. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 6. Effects of Allopurinol Dose Escalation on Bone Erosion and Urate Volume in Gout: A Dual-Energy Computed Tomography Imaging Study Within a Randomized, Controlled Trial.
    Dalbeth N, Billington K, Doyle A, Frampton C, Tan P, Aati O, Allan J, Drake J, Horne A, Stamp LK.
    Arthritis Rheumatol; 2019 Oct 15; 71(10):1739-1746. PubMed ID: 31081595
    [Abstract] [Full Text] [Related]

  • 7. Comparison of two plasma urate assays in patients receiving vitamin C supplementation.
    Sies CW, Florkowski CM, Frampton CM, O'Donnell JL, Chapman PT, Stamp LK.
    Pathology; 2014 Jun 15; 46(4):333-5. PubMed ID: 24798153
    [Abstract] [Full Text] [Related]

  • 8. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul 15; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.
    Arthritis Care Res (Hoboken); 2012 Feb 15; 64(2):256-61. PubMed ID: 22052584
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A, MacDonald PA, Chefo S, Gunawardhana L.
    Postgrad Med; 2013 Jan 15; 125(1):106-14. PubMed ID: 23391676
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.
    J Rheumatol; 2009 Jun 15; 36(6):1273-82. PubMed ID: 19286847
    [Abstract] [Full Text] [Related]

  • 16. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
    N Engl J Med; 2005 Dec 08; 353(23):2450-61. PubMed ID: 16339094
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.